Morgan Stanley raised the firm’s price target on Fresenius Medical (FMS) to EUR 43 from EUR 41 and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Faces FTC Probe and Sells Latin American Clinics Amidst Labor Strikes
- Fresenius Medical price target raised to $30 from $25 at Truist
- Fresenius Medical Care (FMS) Discloses Q2 Dividend: What Shareholders Should Know
- Fresenius Medical Care Q1 2025 Earnings Call Highlights
- Fresenius Medical Care: Balanced Outlook with Hold Rating Amid Mixed Growth Signals